Marc Rendell
YOU?
Author Swipe
View article: An Independent Analysis of a Retrospective Cohort of 30,423 Covid-19 Patients Treated at IHU-Mediterranean in Marseille, France: Part 1, Efficacy of early Treatment with Hydroxychloroquine and Azithromycin
An Independent Analysis of a Retrospective Cohort of 30,423 Covid-19 Patients Treated at IHU-Mediterranean in Marseille, France: Part 1, Efficacy of early Treatment with Hydroxychloroquine and Azithromycin Open
A cohort of 30,423 Covid-19 patients treated between March 2020 and December 2021 at the IHU-Méditerranée Infection in Marseille (France) was retrospectively analyzed in terms of treatment attempted and disease worsening factors to quantif…
View article: An Independent Analysis of a Retrospective Cohort of 30,423 Covid-19 Patients Treated at IHU-Mediterranean in Marseille, France: Part 2, a Real-life Assessment of Covid-19 Vaccination Efficacy
An Independent Analysis of a Retrospective Cohort of 30,423 Covid-19 Patients Treated at IHU-Mediterranean in Marseille, France: Part 2, a Real-life Assessment of Covid-19 Vaccination Efficacy Open
A cohort of 30,423 Covid-19 patients treated between March 2020 and December 2021 at the IHU-Méditerranée Infection in Marseille (France) was retrospectively analyzed in terms of treatment attempted and disease worsening factors to quantif…
View article: Review of: "Tocilizumab Plus Corticosteroid in Elderly Patients Hospitalized With COVID-19 Pneumonia: A Retrospective Cohort Study"
Review of: "Tocilizumab Plus Corticosteroid in Elderly Patients Hospitalized With COVID-19 Pneumonia: A Retrospective Cohort Study" Open
This Article Supports the Importance of Randomized Control StudiesAlthough efforts can be made to compare supposedly equivalent groups in small studies, all things may not always be equal.Clinical decision making based on individual case f…
View article: Review of: "A Villain in Disguise in the Management of Painful Peripheral Neuropathy: A Case Report"
Review of: "A Villain in Disguise in the Management of Painful Peripheral Neuropathy: A Case Report" Open
Potential competing interests: No potential competing interests to declare.The medical literature is dominated by the Western countries.So, an article like this highlighting drug resistant tuberculosis is most welcome and enlightening.The …
View article: Data from Analysis of the <i>CDKN2A</i> Gene in FAMMM Syndrome Families Reveals Early Age of Onset for Additional Syndromic Cancers
Data from Analysis of the <i>CDKN2A</i> Gene in FAMMM Syndrome Families Reveals Early Age of Onset for Additional Syndromic Cancers Open
Familial atypical multiple mole melanoma (FAMMM) syndrome is a hereditary cancer syndrome that results from mutations in several genes, including the CDKN2A gene. In addition to melanoma, certain other malignancies such as pancreati…
View article: Tables S1-S9 and Figures S1-S5 from Analysis of the <i>CDKN2A</i> Gene in FAMMM Syndrome Families Reveals Early Age of Onset for Additional Syndromic Cancers
Tables S1-S9 and Figures S1-S5 from Analysis of the <i>CDKN2A</i> Gene in FAMMM Syndrome Families Reveals Early Age of Onset for Additional Syndromic Cancers Open
Table S1: CDKN2A mutations found in each family; Table S2: Cancers found in each family; Table S2b: Full cancer names and abbreviations; Table S3: Order of cancer occurrence for individuals with multiple primaries; Table S4: Summary statis…
View article: Data from Analysis of the <i>CDKN2A</i> Gene in FAMMM Syndrome Families Reveals Early Age of Onset for Additional Syndromic Cancers
Data from Analysis of the <i>CDKN2A</i> Gene in FAMMM Syndrome Families Reveals Early Age of Onset for Additional Syndromic Cancers Open
Familial atypical multiple mole melanoma (FAMMM) syndrome is a hereditary cancer syndrome that results from mutations in several genes, including the CDKN2A gene. In addition to melanoma, certain other malignancies such as pancreati…
View article: Tables S1-S9 and Figures S1-S5 from Analysis of the <i>CDKN2A</i> Gene in FAMMM Syndrome Families Reveals Early Age of Onset for Additional Syndromic Cancers
Tables S1-S9 and Figures S1-S5 from Analysis of the <i>CDKN2A</i> Gene in FAMMM Syndrome Families Reveals Early Age of Onset for Additional Syndromic Cancers Open
Table S1: CDKN2A mutations found in each family; Table S2: Cancers found in each family; Table S2b: Full cancer names and abbreviations; Table S3: Order of cancer occurrence for individuals with multiple primaries; Table S4: Summary statis…
View article: Review for "Waist circumference thresholds predicting incident dysglycaemia and type 2 diabetes in Black African men and women"
Review for "Waist circumference thresholds predicting incident dysglycaemia and type 2 diabetes in Black African men and women" Open
View article: Review for "Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials"
Review for "Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials" Open
View article: Review for "Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus®) in Chinese adults with type 2 diabetes mellitus: A Phase III , randomised, open‐label, controlled trial"
Review for "Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus®) in Chinese adults with type 2 diabetes mellitus: A Phase III , randomised, open‐label, controlled trial" Open
View article: The time to offer treatments for COVID-19
The time to offer treatments for COVID-19 Open
Background: COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health strategy…
View article: The Importance of Understanding the Stages of COVID-19 in Treatment and Trials
The Importance of Understanding the Stages of COVID-19 in Treatment and Trials Open
COVID-19, caused by SARS-CoV-2, continues to be a major health problem since its first description in Wuhan, China, in December 2019. Multiple drugs have been tried to date in the treatment of COVID-19. Critical to treatment of COVID-19 an…
View article: Review for "Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus®) in Chinese adults with type 2 diabetes mellitus: A Phase III , randomised, open‐label, controlled trial"
Review for "Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus®) in Chinese adults with type 2 diabetes mellitus: A Phase III , randomised, open‐label, controlled trial" Open
View article: The time to offer treatments for COVID-19
The time to offer treatments for COVID-19 Open
Background: COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health strategy…
View article: The time to offer treatments for COVID-19
The time to offer treatments for COVID-19 Open
Background: COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health strategy…
View article: Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients Open
BACKGROUND. Type 1 diabetes (T1D) results from destruction of pancreatic β cells by autoreactive effector T cells. We hypothesized that the immunomodulatory drug alefacept would result in targeted quantitative and qualitative changes in ef…
View article: Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes Open
To assess the safety and efficacy of dual sodium–glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes.
View article: THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19
THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19 Open
BACKGROUND The spread of COVID-19 from Wuhan China, has been alarmingly rapid. Epidemiologic techniques succeeded in containing the disease in China, but efforts have not been as successful in the rest of the World, with a total of 29,155,…
View article: Author response for "COMMENTARY: SGLT inhibitors in type 1 diabetes: place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis ‐ the STOP DKA Protocol"
Author response for "COMMENTARY: SGLT inhibitors in type 1 diabetes: place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis ‐ the STOP DKA Protocol" Open
View article: <p>The journey from gene knockout to clinical medicine: telotristat and sotagliflozin</p>
The journey from gene knockout to clinical medicine: telotristat and sotagliflozin Open
Gene knockout has been a powerful technique to evaluate the physiologic role of selected gene products. Lexicon pioneered high-throughput gene knockout technology and went further in designing agents to inhibit products of gene expression.…
View article: Contents
Contents Open
View article: United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes Open
Marc Rendell1,2 1The Rose Salter Medical Research Foundation, 2The Association of Diabetes Investigators, Newport Coast, CA, USA Abstract: Insulin degludec has been the product of a sophisticated and systematic biochemical engineering prog…
View article: United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes Open
Insulin degludec has been the product of a sophisticated and systematic biochemical engineering program which began with the release of insulin detemir. The goal was to produce a long-lasting basal insulin with low individual variability. …
View article: Long-Term Performance of Point-of-Care Hemoglobin A1c Assays
Long-Term Performance of Point-of-Care Hemoglobin A1c Assays Open
Background: Point-of-care (POC) testing of HbA1c is used as a time-efficient tool to improve treatment and management planning for diabetes in the clinic setting. HbA1c values are the basis for monitoring ongoing response to treatment and …
View article: Screening for familial and hereditary prostate cancer
Screening for familial and hereditary prostate cancer Open
Prostate cancer (PC) has the highest degree of genetic transmission of any form of malignancy. In some families, the hereditary pattern is so strong as to mimic an autosomal dominance trait. We reviewed the known predisposing genetic marke…
View article: Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise Open
View article: Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients Open
BACKGROUND. Type 1 diabetes (T1D) results from destruction of pancreatic β cells by autoreactive effector T cells. We hypothesized that the immunomodulatory drug alefacept would result in targeted quantitative and qualitative changes in ef…
View article: Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients Open
NIH and Astellas.
View article: Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial Open
This study was planned and conducted by Novartis.